Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium.

J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11.

PMID:
26779831
2.

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.

Clarelli F, Liberatore G, Sorosina M, Osiceanu AM, Esposito F, Mascia E, Santoro S, Pavan G, Colombo B, Moiola L, Martinelli V, Comi G, Martinelli-Boneschi F.

Pharmacogenomics J. 2015 Dec 8. doi: 10.1038/tpj.2015.85. [Epub ahead of print]

PMID:
26644207
3.

Gene set differential analysis of time course expression profiles via sparse estimation in functional logistic model with application to time-dependent biomarker detection.

Kayano M, Matsui H, Yamaguchi R, Imoto S, Miyano S.

Biostatistics. 2016 Apr;17(2):235-48. doi: 10.1093/biostatistics/kxv037. Epub 2015 Sep 28.

PMID:
26420796
4.

Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.

Bertoli D, Serana F, Sottini A, Cordioli C, Maimone D, Amato MP, Centonze D, Florio C, Puma E, Capra R, Imberti L.

PLoS One. 2015 Aug 18;10(8):e0135441. doi: 10.1371/journal.pone.0135441. eCollection 2015.

5.

IFN-β Selectively Inhibits IL-2 Production through CREM-Mediated Chromatin Remodeling.

Otero DC, Fares-Frederickson NJ, Xiao M, Baker DP, David M.

J Immunol. 2015 Jun 1;194(11):5120-8. doi: 10.4049/jimmunol.1403181. Epub 2015 Apr 17.

6.

Effects of disruption of the nucleotide pattern in CRID element and Kozak sequence of interferon β on mRNA stability and protein production.

Kay M, Hojati Z, Heidari M, Bazi Z, Korbekandi H.

Autoimmunity. 2015;48(5):336-43. doi: 10.3109/08916934.2015.1022164. Epub 2015 Mar 23.

PMID:
25799196
7.

In vivo maintenance of human regulatory T cells during CD25 blockade.

Huss DJ, Mehta DS, Sharma A, You X, Riester KA, Sheridan JP, Amaravadi LS, Elkins JS, Fontenot JD.

J Immunol. 2015 Jan 1;194(1):84-92.

8.

Multiple sclerosis: effects of IFN-β treatment on vitamin D levels in multiple sclerosis are modified by genetic variants.

Fyfe I.

Nat Rev Neurol. 2014 Dec;10(12):672. doi: 10.1038/nrneurol.2014.210. Epub 2014 Nov 4. No abstract available.

PMID:
25366113
9.

Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.

Yu L, Croze E, Yamaguchi KD, Tran T, Reder AT, Litvak V, Volkert MR.

J Interferon Cytokine Res. 2015 Mar;35(3):186-99. doi: 10.1089/jir.2014.0115. Epub 2014 Oct 20.

10.

Modulating effects of WT1 on interferon-β-vitamin D association in MS.

Lin R, Taylor BV, Charlesworth J, van der Mei I, Blizzard L, Stewart N, Ponsonby AL, Dwyer T, Pittas F, Simpson S Jr.

Acta Neurol Scand. 2015 Apr;131(4):231-9. doi: 10.1111/ane.12315. Epub 2014 Oct 14.

PMID:
25312909
11.

Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis.

Sundal C, Baker M, Karrenbauer V, Gustavsen M, Bedri S, Glaser A, Myhr KM, Haugarvoll K, Zetterberg H, Harbo H, Kockum I, Hillert J, Wszolek Z, Rademakers R, Andersen O.

Eur J Neurol. 2015 Feb;22(2):328-33. doi: 10.1111/ene.12572. Epub 2014 Oct 13.

12.

A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function.

Stürner KH, Borgmeyer U, Schulze C, Pless O, Martin R.

J Immunol. 2014 Nov 1;193(9):4439-47. doi: 10.4049/jimmunol.1303077. Epub 2014 Sep 26.

13.

In vitro biological characterization of IFN-β-1a major glycoforms.

Mastrangeli R, Rossi M, Mascia M, Palinsky W, Datola A, Terlizzese M, Bierau H.

Glycobiology. 2015 Jan;25(1):21-9. doi: 10.1093/glycob/cwu082. Epub 2014 Aug 11.

14.

Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A.

PLoS One. 2014 Jul 15;9(7):e102331. doi: 10.1371/journal.pone.0102331. eCollection 2014.

15.

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO.

Pharmacogenomics. 2014 Apr;15(5):679-85. doi: 10.2217/pgs.14.26.

PMID:
24798724
16.

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.

Núñez C, Cénit MC, Alvarez-Lafuente R, Río J, Fernández-Arquero M, Arroyo R, Montalbán X, Fernández O, Oliver-Martos B, Leyva L, Comabella M, Urcelay E.

J Med Genet. 2014 Jun;51(6):395-400. doi: 10.1136/jmedgenet-2014-102348. Epub 2014 Apr 19.

PMID:
24748646
17.

[The activation of the type I interferon signaling pathway in multiple sclerosis patients treated with russian analogue of Β-interferon-1b: transcriptome profiling data.]

Danilova LV, Popova EV, Kulakova OG, Tsareva EI, Favorov AV, Favorova OO, Boĭko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(2 Vypusk 2 Rasseiannyi skleroz):72-77. Russian.

PMID:
24662360
18.

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.

Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, Kockum I, Hillert J, Fogdell-Hahn A.

PLoS One. 2014 Mar 7;9(3):e90479. doi: 10.1371/journal.pone.0090479. eCollection 2014.

19.

Association of multiple sclerosis susceptibility variants and early attack location in the CNS.

Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E.

PLoS One. 2013 Oct 10;8(10):e75565. doi: 10.1371/journal.pone.0075565. eCollection 2013.

20.

Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells.

Henig N, Avidan N, Mandel I, Staun-Ram E, Ginzburg E, Paperna T, Pinter RY, Miller A.

PLoS One. 2013 Apr 23;8(4):e62366. doi: 10.1371/journal.pone.0062366. Print 2013.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk